-
Mashup Score: 100
Abstract. Purpose: Current NCCN guidelines recommend afatinib or osimertinib as the preferred first-line treatment strategy for patients with advanced NSCLC harboring EGFR p.G719X mutation. However, in the absence of head-to-head trials comparing afatinib with osimertinib in EGFR p.G719X mutant patients, it is unclear which regimen is the preferred treatment option. Experimental Design: A large cohort of 4228 treatment-naïve patients with lung cancer who underwent targeted NGS testing was screened for EGFR p.G719X mutation. A multicenter cohort involving 68 EGFR p.G719X-mutant patients with advanced NSCLC and NGS profiling was retrospectively enrolled to evaluate clinical responses to afatinib(n=37) and the third-generation EGFR-TKIs(n=31). Ba/F3 cells stably expressing the EGFR p.G719A mutation were created to investigate the response to EGFR-TKIs in vitro. Results: Concurrent EGFR p.E709X mutations, being the most frequent co-occurring EGFR mutation in EGFR p.G719X-mutant NSCLC(~30%)
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 115
Mutations in the epidermal growth factor receptor (EGFR) occur in approximately 20 % of North American patients with metastatic non-small cell lung cancer (NSCLC) [1]. The discovery of EGFR directed tyrosine kinase inhibitors (TKIs) has dramatically improved the outcomes of patients with EGFR mutant NSCLC [2,3]. Osimertinib is a third-generation EGFR TKI that was evaluated in FLAURA, a randomized phase three clinical trial against platinum-based chemotherapy. [4] A superior mOS of 39 months was observed.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 32
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of first-line amivantamab plus chemotherapy for NSCLC wit …
Source: www.iaslc.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 88Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201 - 2 month(s) ago
Targeted treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is the current standard of care for EGFR-mutated advanced/metastatic non-small cell lung cancer (NSCLC), which typically exhibits a five-year survival rate of 25–30 % [1,2]. Notably, in Asia, nearly half of the patients diagnosed with lung adenocarcinoma harbor classical activating EGFR mutations (exon 19 deletions [Ex19Del] and L858R point mutation in exon 21 [3]. Patients with these mutations were found to exhibit favorable clinical responses to first-generation EGFR TKIs [4].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 77
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Osimertinib has been established as a standard of care for patients with common sensitizing EGFR-mutant advanced non–small-cell lung cancer (NSCLC) although the sequential approach (first-generation inhibitor gefitinib followed by osimertinib) has not been formally compared. The phase II APPLE trial (ClinicalTrials.gov identifier: NCT02856893) enrolled 156 treatment-naïve patients, and two treatment strategies were evaluated: osimertinib up front or the sequential treatment approach with gefitinib up front followed by osimertinib at the time of progression, either molecu
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 60A retrospective real-world study of prognostic factors associated with EGFR mutated lung cancer with leptomeningeal metastasis - 3 month(s) ago
To analyze the factors associated with EGFR mutated lung cancer with leptomeningeal metastasis (LM) in the real world that affect the prognosis of patients.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 108Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report - 3 month(s) ago
Adjuvant osimertinib represents a recent paradigm shift in the management of resected EGFR-mutated lung cancer. The optimal subsequent treatment of patients who relapse after completion of 3 years of adjuvant osimertinib is unknown. Here, we report two cases of complete response to osimertinib rechallenge after relapse from previous adjuvant osimertinib use, and a serial molecular panel exhibiting a lack of acquired resistance mechanisms. Future prospective studies are warranted to confirm the optimal treatment of patients who relapse after previous adjuvant osimertinib.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 75
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Osimertinib has been established as a standard of care for patients with common sensitizing EGFR-mutant advanced non–small-cell lung cancer (NSCLC) although the sequential approach (first-generation inhibitor gefitinib followed by osimertinib) has not been formally compared. The phase II APPLE trial (ClinicalTrials.gov identifier: NCT02856893) enrolled 156 treatment-naïve patients, and two treatment strategies were evaluated: osimertinib up front or the sequential treatment approach with gefitinib up front followed by osimertinib at the time of progression, either molecu
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 73
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Osimertinib has been established as a standard of care for patients with common sensitizing EGFR-mutant advanced non–small-cell lung cancer (NSCLC) although the sequential approach (first-generation inhibitor gefitinib followed by osimertinib) has not been formally compared. The phase II APPLE trial (ClinicalTrials.gov identifier: NCT02856893) enrolled 156 treatment-naïve patients, and two treatment strategies were evaluated: osimertinib up front or the sequential treatment approach with gefitinib up front followed by osimertinib at the time of progression, either molecu
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 71
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Osimertinib has been established as a standard of care for patients with common sensitizing EGFR-mutant advanced non–small-cell lung cancer (NSCLC) although the sequential approach (first-generation inhibitor gefitinib followed by osimertinib) has not been formally compared. The phase II APPLE trial (ClinicalTrials.gov identifier: NCT02856893) enrolled 156 treatment-naïve patients, and two treatment strategies were evaluated: osimertinib up front or the sequential treatment approach with gefitinib up front followed by osimertinib at the time of progression, either molecu
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
While osimertinib and afatinib are both active in #EGFR G719X mutant NSCLC, report @CCR_AACR shows that the E709X co-mutation mediates primary resistance to 3G EGFR TKIs and afatinib may be the better choice when present. https://t.co/DJiwIXulRt